SB 1223 would add three new sections to Missouri law requiring special disclosures for certain products sold in the state, especially products that may function as gene therapy products or that could expose people to genetically modified material. The bill defines broad categories of covered products, including foods, cosmetics, and other substances intended to be ingested, applied to the body, or otherwise produce physiological effects. If a product is known to be a gene therapy product, it must be labeled “Gene Therapy Product”; if it may potentially act as one, it must be labeled “Potential Gene Therapy Product.” The bill also directs that reasonable steps be taken to ensure purchasers or users are aware of the label.
The bill further requires any entity that produces, sells, or distributes certain products with the capacity to infect an individual with a disease or expose an individual to genetically modified material—including vaccines, gene therapies, drugs, and medical interventions—to provide, upon written request from a Missouri resident, all information about how non-users or bystanders may be exposed to the product or its components. The requested information must be provided within 21 days and may include reports, research, and other knowledge held by manufacturers, government agencies, or organizations with an interest in the product. A separate section would require entities making such products available in Missouri to obtain fully informed consent from all individuals who could be exposed before exposure occurs, including disclosure of benefits, risks, side effects, adverse events of special interest, and other reasonably possible impacts.
If enacted, SB 1223 would significantly expand disclosure obligations for manufacturers, distributors, and other entities involved with a wide range of health-related and body-applied products. It would create new labeling and information-sharing duties in chapter 196, RSMo, and could affect product marketing, consumer warnings, and compliance practices for food, cosmetic, pharmaceutical, vaccine, and biotechnology-related products. The bill’s language is broad and could be read to reach products and exposures beyond traditional gene therapy contexts.
The available context shows no committee transcript, recorded votes, or formal action history, so there is no documented legislative debate or vote-based sentiment to assess. Based on the bill text alone, the measure appears to be driven by a strong disclosure-and-consent approach, but it also uses expansive definitions that could raise implementation and interpretation concerns. Because no discussion record is available, any sentiment assessment is limited to the bill’s stated policy direction rather than expressed legislative support or opposition.
Notable points of contention likely include the bill’s very broad definitions of “product,” “gene therapy product,” and “expose,” which could sweep in vaccines, drugs, medical interventions, foods, cosmetics, and other substances. The requirement that entities provide extensive information on request, including materials held by government agencies or organizations with an interest in the product, may also be controversial. Another likely point of dispute is the fully informed consent requirement for anyone who could be exposed, which is unusual in scope and may be difficult to apply in practice.
The bill would add new disclosure, labeling, and consent requirements to chapter 196 of the Missouri Revised Statutes. It would impose obligations on manufacturers, sellers, distributors, and related entities to label certain products, respond to resident information requests, and obtain informed consent before exposure to covered products. These provisions could affect regulatory compliance for food, cosmetic, pharmaceutical, vaccine, and biotechnology-related products and create new enforcement or interpretation issues under Missouri consumer and health law.
There is no recorded committee discussion or voting history in the provided materials, so no direct legislative sentiment can be measured. The bill’s text reflects a strong pro-disclosure and pro-consent policy stance, suggesting its sponsor intended to maximize consumer awareness and control. At the same time, the breadth of the bill’s definitions and obligations suggests it could draw skepticism from stakeholders concerned about feasibility, scope, and overlap with existing federal and state product regulation.
The main points of contention are likely to be the bill’s expansive reach and the practicality of its requirements. Opponents may argue that the definitions of covered products and exposure are overly broad and could unintentionally include ordinary consumer goods and standard medical products. They may also object to the mandate to provide all relevant reports, research, and knowledge on request, and to the requirement for fully informed consent from all potentially exposed individuals, which could be difficult to administer. Supporters would likely emphasize transparency, consumer choice, and disclosure of potential genetic or biological effects.